AbbVie Inc. $ABBV Stock Holdings Trimmed by Vaughan Nelson Investment Management L.P.

Vaughan Nelson Investment Management L.P. reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 58.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,760 shares of the company’s stock after selling 12,375 shares during the quarter. Vaughan Nelson Investment Management L.P.’s holdings in AbbVie were worth $2,002,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Ellenbecker Investment Group lifted its stake in shares of AbbVie by 0.8% in the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after acquiring an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA raised its holdings in AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after purchasing an additional 45 shares in the last quarter. Matthew Goff Investment Advisor LLC raised its holdings in AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after purchasing an additional 45 shares in the last quarter. Centennial Wealth Advisory LLC lifted its position in AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after purchasing an additional 45 shares during the period. Finally, Willner & Heller LLC boosted its stake in AbbVie by 0.6% during the 3rd quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after purchasing an additional 46 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: BMO/analyst reaffirmation: BMO maintained a Buy on ABBV with a $258 target, citing immunology strength, strategic M&A and confidence in managing patent headwinds — this supports upside expectations. AbbVie: Immunology Strength, Strategic Acquisitions, and Patent Headwind Execution Support Buy Rating
• Positive Sentiment: Allergan Aesthetics promotions and safety data: marketing pushes (CoolMonth discounts) and AAD poster data on aesthetics products can help near-term revenue and consumer demand in the aesthetics division. Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®
• Positive Sentiment: Lower corporate cash taxes across US companies: analyses show a multibillion-dollar drop in cash taxes after recent tax changes — a tailwind to free cash flow and net income for large pharma including AbbVie. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
• Neutral Sentiment: Upcoming earnings call (April 29): Management will report Q1 results and the FY guidance cadence remains the main near-term catalyst; investors are positioning ahead of the print. AbbVie to Host First-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Market context: reports note ABBV shares have risen recently but still underperform broader market — indicating selective investor interest and potential for mean reversion or further outperformance depending on upcoming results. AbbVie Inc. stock rises Tuesday, still underperforms market
• Negative Sentiment: Litigation around Cerevel deal: a court ordered Pfizer and Bain to litigate a suit by Cerevel investors over AbbVie’s deal — increased legal/transactional scrutiny could raise deal costs or disclosure risk. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
• Negative Sentiment: Oncology headwinds: analyst commentary flags pricing pressure on Imbruvica that could blunt oncology revenue growth in 2026 despite contributions from newer oncology assets. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?
• Negative Sentiment: Competitive oncology moves: Merck’s recent oncology acquisition strengthens a rival pipeline, adding competitive pressure to long-term oncology growth assumptions. Merck Just Made a Big Bet on a New Cancer Growth Engine

AbbVie Trading Up 2.0%

Shares of ABBV opened at $217.39 on Wednesday. The business’s 50-day moving average price is $222.00 and its 200 day moving average price is $224.65. The stock has a market capitalization of $384.38 billion, a P/E ratio of 92.11, a P/E/G ratio of 0.74 and a beta of 0.34. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same period last year, the company posted $2.16 earnings per share. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is 293.22%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ABBV. Morgan Stanley boosted their price objective on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. William Blair reiterated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. UBS Group cut their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $253.15.

Insider Buying and Selling at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.08% of the stock is owned by insiders.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.